Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage a
Open label, single arm, multicenter phase II trial.
Chronic Lymphoid Leukemia
DRUG: Venetoclax
Complete response rate, according to International Workshop Chronic Lymphoid Leukemia 2008 guidelines and with Minimal Residual Disease inferior to 0.01 percent (as determined by 8-color technique) in bone marrow at month 12., 12 months
Preemptive therapy with Venetoclax for high risk stage A Chronic Lymphoid Leukemia patients, a phase II trial of the FILO group.

PREVENE (PREemptive VENEtoclax) trial.